血清CA125水平结合ProMisE分子分型可提供术前预后信息并指导子宫内膜癌管理
本研究在1107例分子分型的子宫内膜癌(EC)患者中评估CA125与宫外/淋巴结转移及分子亚型的关系。CA125>35 kU/L与更高分期和淋巴结转移相关,且与总生存、疾病特异性生存和无进展生存更差相关。CA125>35 kU/L对淋巴结转移的敏感度为0.82、特异度0.53、阳性预测值0.92、阴性预测值0.31。
要点
- CA125>35 kU/L与EC所有分子亚型中更高分期和淋巴结转移相关(单因素p<0.01,多因素p<0.05)。
- CA125>35 kU/L对淋巴结转移的敏感度0.82、特异度0.53、阳性预测值0.92、阴性预测值0.31。
- CA125>35 kU/L与III/IV期疾病的相对风险(RR)为2.50,与同步子宫内膜和卵巢癌/共存附件恶性肿瘤的RR为18.4。
核心结论
- CA125水平与分子亚型、分期>I期疾病及同步子宫内膜和卵巢癌/共存附件恶性肿瘤相关。
- 在分子分型时代,CA125仍是子宫内膜癌分诊中有用的临床工具。
研究设计与样本
- 研究对1107例经分子分型的子宫内膜癌(EC)患者队列评估了CA125水平与临床病理及结局数据的关联。
主要发现
- CA125异常(>35 kU/L)在所有EC及每个分子亚型中与更高分期和淋巴结转移(LNM)相关(单因素p<0.01,多因素p<0.05)。
- POLEmut亚型的中位CA125水平和CA125异常患者比例最低,p53abn亚型的CA125异常患者比例最高(p<0.001)。
- CA125>35 kU/L对LNM的敏感度为0.82、特异度为0.53、阳性预测值为0.92、阴性预测值为0.31,对分期>I期的值相似。
- CA125>35 kU/L与所有EC及p53abn(OS、DSS、PFS)、NSMP(OS、DSS)、MMRd(OS、DSS)亚型更差的总生存(OS)、疾病特异性生存(DSS)和无进展生存(PFS)相关。
- CA125>35 kU/L与III/IV期疾病的相对风险(RR)为2.50(p<0.001),与同步子宫内膜和卵巢癌(SEOC)/共存附件恶性肿瘤(CAM)的RR为18.4(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous research suggests serum CA125 reflects extra-uterine disease in patients with endometrial carcinoma (EC). Our objective was to determine if CA125 can identify patients with extra-uterine and/or nodal metastases, the association of this biomarker with EC molecular subtype, and to explore an optimal cutoff in this context. METHODS: We assessed the association of CA125 levels with clinicopathologic and outcomes data on a cohort of 1107 molecularly classified EC. RESULTS: Abnormal CA125 (>35kU/L) was associated with higher stage and lymph node metastases (LNM) in all EC and in each molecular subtype on univariate (p < 0.01) and multivariate (p < 0.05) analyses. POLEmut had the lowest median CA125 level and proportion of CA125 abnormal patients, and p53abn the highest proportion (p < 0.001). CA125 > 35 kU/L had a sensitivity of 0.82, specificity 0.53, positive-predictive-value 0.92, and negative-predictive-value 0.31 for LNM, with similar values for stage>I. CA125 > 35 kU/L was associated with worse overall (OS), disease-specific (DSS), and progression-free survival (PFS) in all EC, p53abn (OS, DSS, PFS), NSMP (OS, DSS), and MMRd (OS, DSS) subtypes. CA125 > 35 kU/L demonstrated a relative risk (RR) of 2.50 with presence of stage III/IV disease (p < 0.001) and RR 18.4 for the presence of synchronous endometrial and ovarian carcinomas (SEOC)/co-existing adnexal malignancies (CAM) (p < 0.001). An exploratory cut point, optimized for correlation with DSS (CA125 > 24 kU/L) show similar association with clinical parameters and survival outcome. CONCLUSIONS: CA125 levels are associated with molecular subtype, stage>I disease, and SEOC/CAM. CA125 remains a useful clinical tool in the triage of EC in the era of molecular classification.
引用
- Neilson A, Jamieson A, Chiu D, et al. Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management. Gynecol Oncol. 2024. PMID: 39740305. doi:10.1016/j.ygyno.2024.12.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。